Traitements médicamenteux préventifs des ostéoporoses

Osteoporosis and fragility fractures represent a public health issue, responsible for an increased morbidity and mortality. We should consider the prevention of this chronic disease. We can differentiate primary prevention, meaning bone loss prevention in patients with normal bone density, and secondary prevention, meaning fracture prevention in patients with low bone density. We will not discuss about tertiary prevention, which is prevention of fracture recurrence. We will discuss here drug prevention treatment in post-menopausal women, in cancer with hormonotherapy, and in cortico-induced osteoporosis.